Rph.Bk
RPH.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
Business. RPH.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RPH.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
RPH.BK maintains a strong liquidity position, with a current ratio of 3.63, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity is supported by a total equity of 1,715,427,200 THB and a minimal long-term debt of 3,287,600 THB, resulting in a debt-to-equity ratio of 0.0. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag.
In terms of profitability, RPH.BK demonstrates a return on equity (ROE) of 10.63% and a return on assets (ROA) of 9.56%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets, aligning with industry expectations for healthcare providers and services.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in the event of a downturn in its primary market or product line.
Looking ahead, RPH.BK is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of -84,986,840 THB indicates a reduction in investment in physical assets, which may reflect a strategic shift toward cost optimization or a focus on operational efficiency.
The company faces a medium liquidity risk due to its negative net cash position, despite having a strong current ratio. The risk of dilution is low, as the company has not issued additional shares in the recent period, and there is no indication of future dilutive events in the available data. However, the absence of detailed information on potential dilution sources limits the ability to fully assess this risk.
Recent filings and transcripts do not indicate any major events or strategic shifts for RPH.BK in the last reporting period. The company appears to be maintaining a steady course, with no significant new product launches or market expansions disclosed in the available data.
- RPH.BK has a strong liquidity position with a current ratio of 3.63 and minimal long-term debt.
- The company generates solid returns, with a ROE of 10.63% and a ROA of 9.56%.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company is projected to maintain stable growth with no significant changes in revenue expected.
- Liquidity risk is medium due to a negative net cash position, despite strong short-term liquidity metrics.
- The risk of dilution is low, with no recent or anticipated share issuance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- RPH.BK Market data — financials · 2026-05-29